Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: An effective salvage therapy option for acute myeloid leukemia at first relapse

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 336-341

  Fong, Chun Yew ^a   Grigoriadis, George ^a,b   Hocking, Jay ^c   Coutsouvelis, John ^a,d   Muirhead, Jenny ^a   Campbell, Philip ^e   Paul, Eldho ^b   Walker, Patricia ^a,b   Avery, Sharon ^a,b   Patil, Sushrut ^a,b   Spencer, Andrew ^a,b   Schwarer, Anthony ^a,c   Wei, Andrew ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BOX HILL HOSPITAL   (Australia)

^d Faculty of Pharmacy and Pharmaceutical Sciences   (Canada)

^e Andrew Love Cancer Centre   (Australia)

Author keywords

AML; Amsacrine; Cytarabine; FLAG amsacrine; Fludarabine; Relapse

Indexed keywords

AMSACRINE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CYTOGENETICS; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; GERIATRIC PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AMSACRINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84872048218     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.713479     Document Type: Article

References (37)

1. Bradstock KF, Matthews JP, Lowenthal RM, et al. Arandomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 2005; 105: 481-488.
2. Fernandez H, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. NEngl JMed 2009; 361: 1249-1259.
3. Lee JH, Joo YD, Kim H, et al. Arandomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011; 118: 3832-3841.
4. Lowenberg B, Ossenkoppele G, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. NEngl JMed 2009; 361: 1235-1248.
5. Burnett AK, Milligan D, Goldstone A, et al. Theimpact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br JHaematol 2009; 145: 318-332.
6. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. JClin Oncol 2005; 23: 1969-1978.
7. Giles F, Verstovsek S, Garcia-Manero G, et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br JHaematol 2006; 134: 58-60.
8. Ravandi F, Cortes J, Faderl S, et al. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood 2010; 116: 5818-5823.
9. Chevallier P, Labopin M, Turlure P, et al. Anew Leukemia Prognostic Scoring System for refractory/relapsed adult acute myelogeneous leukaemia patients: aGOELAMS study. Leukemia 2011; 25: 939-944.
10. Greenberg PL, Lee SJ, Advani R, et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: aphase III trial (E2995). JClin Oncol 2004; 22: 1078-1086.
11. Parker J, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br JHaematol 1997; 99: 939-944.
12. Virchis A, Koh M, Rankin P, et al. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br JHaematol 2004; 124: 26-32.
13. Pastore D, Specchia G, Carluccio P, et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: singlecenter experience. Ann Hematol 2003; 82: 231-235.
14. Yavuz S, Paydas S, Disel U, et al. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: asinglecenter experience. Am JTh er 2006; 13: 389-393.
15. Price SL, Lancet JE, George TJ, et al. Salvage chemotherapy regimens for acute myeloid leukemia: is one better? Efficacy comparison between CLAG and MEC regimens. Leuk Res 2011; 35: 301-304.
16. Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: areport from the Eastern Cooperative Oncology Group. Br JHaematol 2010; 148: 217-225.
17. Levis M, Ravandi F, Wang ES, et al. Results from arandomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.
18. Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is ahighly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: afinal report of the Polish Adult Leukemia Group. Eur JHaematol 2008; 80: 115-126.
19. Schmid C, Schleuning M, Schwerdtfeger R, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
20. Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stemcell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. JClin Oncol 2005; 23: 5675-5687.
21. Tauro S, Shankaranarayana P, Nitu-Whalley IC, et al. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia. Bone Marrow Transplant 2003; 32: 273-278.
22. Tavernier E, Le QH, Elhamri M, et al. Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors. Leuk Res 2003; 27: 205-214.
23. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. JClin Oncol 2003; 21: 4642-4649.
24. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
25. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
26. Leopold LH, Willemze R. Thetreatment of acute myeloid leukemia in first relapse: acomprehensive review of the literature. Leuk Lymphoma 2002; 43: 1715-1727.
27. Robak T. Purine nucleoside analogues in the treatment of myleoid leukemias. Leuk Lymphoma 2003; 44: 391-409.
28. Visani G, Tosi P, Zinzani PL, et al. FLAG (fludarabine-highdose cytarabine-G-CSF): an effective and tolerable protocol for the treatment of " poor risk " acute myeloid leukemias. Leukemia 1994; 8: 1842-1846.
29. Tosi P, Visani G, Ottaviani E, et al. Fludarabine-Ara-C-G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8: 2076-2082.
30. Gandhi V, Estey E, Du M, et al. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1995; 1: 169-178.
31. te Boekhorst PA, Lowenberg B, Sonneveld P. Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells. Leukemia 1994; 8: 1480-1486.
32. Estey E, Th all P, AndreeffM, et al. Use of granulocyte colonystimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. JClin Oncol 1994; 12: 671-678.
33. Schmid C, Schleuning M, Tischer J, et al. Early allo-SCT for AML with acomplex aberrant karyotype-results from aprospective pilot study. Bone Marrow Transplant 2012; 47: 46-53.
34. Arellano ML, Langston A, Winton E, et al. Treatment of relapsed acute leukemia after allogeneic transplantation: asingle center experience. Biol Blood Marrow Transplant 2007; 13: 116-123.
35. Ferrara F, Morabito F, Latagliata R, et al. Aggressive salvage treatment is not appropriate for the majority of elderly patients with acute myeloid leukemia relapsed from first complete remission. Haematologica 2001; 86: 814-820.
36. Arlin ZA, Feldman EJ, Mittelman A, et al. Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. Cancer 1991; 68: 1198-1200.
37. Kessler T, Mohr M, Müller-Tidow C, et al. Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in amatched-pair analysis. Leuk Res 2008; 32: 491-494.